Importance of breast cancer subtype in the development of androgen-receptor-directed therapy

Elgene Lim, Min Ni, Shiliang Cao, Aditi Hazra, Rulla M. Tamimi, Myles Brown

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The androgen receptor (AR) has re-emerged as a potential therapeutic target for breast cancer treatment. This stems from recent progress made in preclinical models, which have recognized important differences in the effect of AR expression on outcomes for patients with different breast cancer subtypes. In parallel, the clinical development of new generations of androgen-receptor- directed therapy for prostate cancer has begun to mature. The availability of these new agents has resulted in trials of their potential for treating breast cancer. It is critical that studies of the effect of AR expression and signaling in breast cancer should be context and subtype specific, to successfully translate AR modulation into a clinical strategy for breast cancer. We will review developments in preclinical studies, and recent clinical trials targeting AR in breast cancer.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalCurrent Breast Cancer Reports
Volume6
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Androgen Receptors
Breast Neoplasms
Therapeutics
Prostatic Neoplasms
Clinical Trials

Keywords

  • Androgen receptor
  • Androgen receptor directed therapy
  • Breast cancer
  • Breast cancer subtype

ASJC Scopus subject areas

  • Oncology

Cite this

Importance of breast cancer subtype in the development of androgen-receptor-directed therapy. / Lim, Elgene; Ni, Min; Cao, Shiliang; Hazra, Aditi; Tamimi, Rulla M.; Brown, Myles.

In: Current Breast Cancer Reports, Vol. 6, No. 2, 2014, p. 71-78.

Research output: Contribution to journalArticle

Lim, Elgene ; Ni, Min ; Cao, Shiliang ; Hazra, Aditi ; Tamimi, Rulla M. ; Brown, Myles. / Importance of breast cancer subtype in the development of androgen-receptor-directed therapy. In: Current Breast Cancer Reports. 2014 ; Vol. 6, No. 2. pp. 71-78.
@article{83b4abc288bc44dd8415d9848abbd425,
title = "Importance of breast cancer subtype in the development of androgen-receptor-directed therapy",
abstract = "The androgen receptor (AR) has re-emerged as a potential therapeutic target for breast cancer treatment. This stems from recent progress made in preclinical models, which have recognized important differences in the effect of AR expression on outcomes for patients with different breast cancer subtypes. In parallel, the clinical development of new generations of androgen-receptor- directed therapy for prostate cancer has begun to mature. The availability of these new agents has resulted in trials of their potential for treating breast cancer. It is critical that studies of the effect of AR expression and signaling in breast cancer should be context and subtype specific, to successfully translate AR modulation into a clinical strategy for breast cancer. We will review developments in preclinical studies, and recent clinical trials targeting AR in breast cancer.",
keywords = "Androgen receptor, Androgen receptor directed therapy, Breast cancer, Breast cancer subtype",
author = "Elgene Lim and Min Ni and Shiliang Cao and Aditi Hazra and Tamimi, {Rulla M.} and Myles Brown",
year = "2014",
doi = "10.1007/s12609-014-0140-5",
language = "English (US)",
volume = "6",
pages = "71--78",
journal = "Current Breast Cancer Reports",
issn = "1943-4588",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Importance of breast cancer subtype in the development of androgen-receptor-directed therapy

AU - Lim, Elgene

AU - Ni, Min

AU - Cao, Shiliang

AU - Hazra, Aditi

AU - Tamimi, Rulla M.

AU - Brown, Myles

PY - 2014

Y1 - 2014

N2 - The androgen receptor (AR) has re-emerged as a potential therapeutic target for breast cancer treatment. This stems from recent progress made in preclinical models, which have recognized important differences in the effect of AR expression on outcomes for patients with different breast cancer subtypes. In parallel, the clinical development of new generations of androgen-receptor- directed therapy for prostate cancer has begun to mature. The availability of these new agents has resulted in trials of their potential for treating breast cancer. It is critical that studies of the effect of AR expression and signaling in breast cancer should be context and subtype specific, to successfully translate AR modulation into a clinical strategy for breast cancer. We will review developments in preclinical studies, and recent clinical trials targeting AR in breast cancer.

AB - The androgen receptor (AR) has re-emerged as a potential therapeutic target for breast cancer treatment. This stems from recent progress made in preclinical models, which have recognized important differences in the effect of AR expression on outcomes for patients with different breast cancer subtypes. In parallel, the clinical development of new generations of androgen-receptor- directed therapy for prostate cancer has begun to mature. The availability of these new agents has resulted in trials of their potential for treating breast cancer. It is critical that studies of the effect of AR expression and signaling in breast cancer should be context and subtype specific, to successfully translate AR modulation into a clinical strategy for breast cancer. We will review developments in preclinical studies, and recent clinical trials targeting AR in breast cancer.

KW - Androgen receptor

KW - Androgen receptor directed therapy

KW - Breast cancer

KW - Breast cancer subtype

UR - http://www.scopus.com/inward/record.url?scp=84905725004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905725004&partnerID=8YFLogxK

U2 - 10.1007/s12609-014-0140-5

DO - 10.1007/s12609-014-0140-5

M3 - Article

VL - 6

SP - 71

EP - 78

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 2

ER -